天津科学技术出版社

再生障碍性贫血的免疫病理机制与再生修复策略

胡耐博 1,王化泉 2*
作者信息
  1. 1 天津大学海河医院血液内科,天津 300350
  2. 2 天津医科大学总医院血液科,天津 300052
*通信作者

摘要

再生障碍性贫血(AA)是以全血细胞减少为特征的骨髓造血功能衰竭综合征,曾因治疗手段有限而预后不良。随着免疫学与再生医学的发展,AA的治疗策略经历了从支持治疗到免疫干预、再到免疫与再生并重的范式转变。本文系统阐述AA的免疫病理机制,重点分析免疫系统对造血干/祖细胞(HSPC)的异常攻击、免疫耐受失衡及骨髓微环境损伤,并探讨当前以免疫抑制治疗(IST)和造血干细胞移植(HSCT)为核心的临床策略。同时,本文聚焦再生修复这一新兴治疗维度,系统介绍促血小板生成素受体激动剂(TPO-RA)激发内源性造血再生、间充质干细胞(MSC)输注修复骨髓微环境,以及基因治疗校正遗传缺陷等前沿策略,旨在描绘AA治疗"从免疫破坏到主动再生"的完整图景,为临床实践与未来研究提供参考。


Immune pathogenesis and regenerative strategies in aplastic anemia

Naibo HU 1, Huaquan WANG 2*
Author Information
  1. 1 Department of Hematology, Haihe Hospital, Tianjin University, Tianjin 300350, China
  2. 2 Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
*Corresponding author

Abstract

Aplastic anemia (AA) is a bone marrow hematopoietic failure syndrome characterized by pancytopenia, which has a poor prognosis due to limited treatment. With the development of immunology and regenerative medicine, AA treatment strategies have undergone a paradigm shift from supportive therapy to immune intervention, and then to both immunization and regeneration. In this paper, we systematically describe the immunopathological mechanism of AA, focusing on the abnormal attack of immune system on hematopoietic stem/progenitor cells, immune tolerance imbalance and bone marrow microenvironment damage, and discuss the current clinical strategy centered on immunosuppressive therapy and hematopoietic stem cell transplantation. At the same time, the article looks forward to the regeneration and repair strategies represented by thrombopoietin receptor agonists, mesenchymal stem cell infusion and gene therapy, and emphasizes that AA therapy should be developed in the direction of precision, individualization and combination in order to achieve functional cure and long-term survival improvement.

利益冲突:作者均声明无利益冲突

再生医学研究 Copyright © 2026. All Rights Reserved